Palonosetron (Helsinn).
Palonosetron, a selective 5-HT3 receptor antagonist, is being developed by Helsinn for the potential treatment of chemotherapy-induced nausea and vomiting. By 1999, it was in phase III trials, and as of May 2002, an NDA filing was scheduled for the third quarter of 2002.
Stacher
Georg
G
Department of Surgery, University of Vienna, Austria. georg.stacher@akh-wien.ac.at
D000818:Animals; D000932:Antiemetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D007546:Isoquinolines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D000077924:Palonosetron; D011812:Quinuclidines / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D000932:Antiemetics; D007546:Isoquinolines; D011812:Quinuclidines; D012702:Serotonin Antagonists; D000077924:Palonosetron